 Adjuvants, Immunologic
"Adjuvants, Immunologic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund's adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity.
| Descriptor ID |
D000276
|
| MeSH Number(s) |
D27.505.696.477.067
|
| Concept/Terms |
Adjuvants, Immunologic- Adjuvants, Immunologic
- Immunostimulants
- Adjuvant, Immunologic
- Immunologic Adjuvant
- Immunological Adjuvant
- Adjuvant, Immunological
- Immunoactivators
- Immunoadjuvants
- Immunologic Adjuvants
- Immunopotentiators
- Adjuvants, Immunological
- Immunological Adjuvants
|
Below are MeSH descriptors whose meaning is more general than "Adjuvants, Immunologic".
Below are MeSH descriptors whose meaning is more specific than "Adjuvants, Immunologic".
This graph shows the total number of publications written about "Adjuvants, Immunologic" by people in this website by year, and whether "Adjuvants, Immunologic" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 | | 1997 | 1 | 1 | 2 | | 1998 | 3 | 1 | 4 | | 1999 | 0 | 1 | 1 | | 2000 | 3 | 1 | 4 | | 2001 | 2 | 5 | 7 | | 2002 | 7 | 6 | 13 | | 2003 | 4 | 1 | 5 | | 2004 | 9 | 2 | 11 | | 2005 | 6 | 2 | 8 | | 2006 | 3 | 0 | 3 | | 2007 | 3 | 2 | 5 | | 2008 | 9 | 4 | 13 | | 2009 | 5 | 3 | 8 | | 2010 | 2 | 4 | 6 | | 2011 | 5 | 1 | 6 | | 2013 | 2 | 3 | 5 | | 2014 | 5 | 2 | 7 | | 2015 | 4 | 4 | 8 | | 2016 | 2 | 2 | 4 | | 2017 | 2 | 5 | 7 | | 2018 | 0 | 2 | 2 | | 2019 | 3 | 5 | 8 | | 2020 | 2 | 3 | 5 | | 2021 | 0 | 3 | 3 | | 2022 | 0 | 4 | 4 | | 2023 | 0 | 4 | 4 | | 2024 | 1 | 3 | 4 |
To return to the timeline, click here.
Below are the most recent publications written about "Adjuvants, Immunologic" by people in Profiles.
-
Ou BS, Baillet J, Filsinger Interrante MV, Adamska JZ, Zhou X, Saouaf OM, Yan J, Klich JH, Jons CK, Meany EL, Valdez AS, Carter L, Pulendran B, King NP, Appel EA. Saponin nanoparticle adjuvants incorporating Toll-like receptor agonists drive distinct immune signatures and potent vaccine responses. Sci Adv. 2024 Aug 09; 10(32):eadn7187.
-
Hansen L, Guthmiller JJ. Immunity by AS03ation: The natural adjuvantage. Immunity. 2024 05 14; 57(5):927-929.
-
Massari F, Santoni M, Takeshita H, Okada Y, Tapia JC, Basso U, Maruzzo M, Scagliarini S, B?ttner T, Fornarini G, Myint ZW, Galli L, Souza VC, Pichler R, De Giorgi U, Gandur N, Lam ET, Gilbert D, Popovic L, Grande E, Mammone G, Berardi R, Crabb SJ, Kemp R, Molina-Cerrillo J, Freitas M, Luz M, Iacovelli R, Calabr? F, Tural D, Atzori F, K?ronya Z, Chiari R, Campos S, Caffo O, Fay AP, Kucharz J, Zucali PA, Rinck JA, Zeppellini A, Bastos DA, Aurilio G, Mota A, Trindade K, Ortega C, Sade JP, Rizzo M, Fiala O, Vau N, Giannatempo P, Barillas A, Monteiro FSM, Dauster B, Mennitto A, Nogueira L, de Carvalho Fernandes R, Seront E, Aceituno LG, Grillone F, Cutuli HJ, Fernandez M, Bassanelli M, Kopp RM, Roviello G, Abahssain H, Procopio G, Milella M, Kopecky J, Martignetti A, Messina C, Caitano M, Inman E, Kanesvaran R, Herchhorn D, Santini D, Bamias A, Bisonni R, Mosca A, Morelli F, Maluf F, Soares A, Nunes F, Pinto A, Zgura A, Incorvaia L, Ansari J, Zabalza IO, Landmesser J, Rizzo A, Mollica V, Marchetti A, Rosellini M, Sorgentoni G, Battelli N, Buti S, Porta C, Bellmunt J. Global real-world experiences with pembrolizumab?in advanced?urothelial?carcinoma after platinum-based chemotherapy: the ARON-2 study. Cancer Immunol Immunother. 2024 Apr 18; 73(6):106.
-
Greenblott DN, Wood CV, Zhang J, Viza N, Chintala R, Calderon CP, Randolph TW. Supervised and unsupervised machine learning approaches for monitoring subvisible particles within an aluminum-salt adjuvanted vaccine formulation. Biotechnol Bioeng. 2024 May; 121(5):1626-1641.
-
Desmond LW, Holbrook EM, Wright CTO, Zambrano CA, Stamper CE, Bohr AD, Frank MG, Podell BK, Moreno JA, MacDonald AS, Reber SO, Hern?ndez-Pando R, Lowry CA. Effects of Mycobacterium vaccae NCTC 11659 and Lipopolysaccharide Challenge on Polarization of Murine BV-2 Microglial Cells. Int J Mol Sci. 2023 Dec 29; 25(1).
-
Levin MJ, Divino V, Postma MJ, Pelton SI, Zhou Z, DeKoven M, Mould-Quevedo J. A clinical and economic assessment of adjuvanted trivalent versus standard egg-derived quadrivalent influenza vaccines among older adults in the United States during the 2018-19 and 2019-20 influenza seasons. Expert Rev Vaccines. 2024 Jan-Dec; 23(1):124-136.
-
Smith CL, Bednarchik B, Aung H, Wilk DJ, Boxer RS, Daddato AE, Wilson BM, Gravenstein S, Canaday DH. Humoral and Cellular Immunity Induced by Adjuvanted and Standard Trivalent Influenza Vaccine in Older Nursing Home Residents. J Infect Dis. 2023 09 15; 228(6):704-714.
-
Black PC, Tangen CM, Singh P, McConkey DJ, Lucia MS, Lowrance WT, Koshkin VS, Stratton KL, Bivalacqua TJ, Kassouf W, Porten SP, Bangs R, Plets M, Thompson IM, Lerner SP. Phase 2 Trial of Atezolizumab in Bacillus Calmette-Gu?rin-unresponsive High-risk Non-muscle-invasive Bladder Cancer: SWOG S1605. Eur Urol. 2023 12; 84(6):536-544.
-
de Jong FC, Laajala TD, Hoedemaeker RF, Jordan KR, van der Made ACJ, Boev? ER, van der Schoot DKE, Nieuwkamer B, Janssen EAM, Mahmoudi T, Boormans JL, Theodorescu D, Costello JC, Zuiverloon TCM. Non-muscle-invasive bladder cancer molecular subtypes predict differential response to intravesical Bacillus Calmette-Gu?rin. Sci Transl Med. 2023 05 24; 15(697):eabn4118.
-
Callegaro A, Burny W, Herv? C, Hyung Kim J, Levin MJ, Zahaf T, Cunningham AL, Didierlaurent AM. Association Between Immunogenicity and Reactogenicity: A Post Hoc Analysis of 2 Phase 3 Studies With the Adjuvanted Recombinant Zoster Vaccine. J Infect Dis. 2022 11 28; 226(11):1943-1948.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|